23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need ...
The FDA authorized 23andMe to market its pharmacogenetic report Oct. 31, marking the agency’s first time greenlighting a direct-to-consumer DNA test for this purpose. Pharmacogenetics is an area of ...
Forbes contributors publish independent expert analyses and insights. Ellen Matloff covers genetic counseling, testing and digital health. One in 20 people carries one change in a gene called DPYD. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback